DT 168
Alternative Names: DT-168Latest Information Update: 13 Nov 2024
Price :
$50 *
At a glance
- Originator Design Therapeutics
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Fuchs' endothelial dystrophy
Most Recent Events
- 07 Nov 2024 Phase-I clinical trials in Fuchs' endothelial dystrophy (In volunteers) (unspecified route)
- 05 Aug 2024 Design Therapeutics plans a phase I trial (In volunteers) for Fuchs' endothelial dystrophy in 2024
- 19 Mar 2024 US FDA approves IND application for DT 168 in Fuchs' endothelial dystrophy